Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 3, 2012, Pages 268-280

  Zou, Yunzeng ^a   Lin, Li ^a   Ye, Yong ^a   Wei, Jianming ^a   Zhou, Ning ^a   Liang, Yanyan ^a   Gong, Hui ^a   Li, Lei ^a   Wu, Jian ^a   Li, Yunbo ^b   Jia, Zhenhua ^b   Wu, Yiling ^b   Zhou, Jingmin ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b Yiling Medical Research Institution of Hebei   (China)

Author keywords

cardiac hypertrophy; dysfunction; pressure overload; Qiliqiangxin; remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CHINESE DRUG; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; QILIQIANGXIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART CATHETERIZATION; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUGS, CHINESE HERBAL; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; UP-REGULATION; VENTRICULAR REMODELING;

EID: 84858795478     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823f888f     Document Type: Article

References (45)

1. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echo-cardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566. (Pubitemid 20176696)
2. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
3. Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38:1829-1835. (Pubitemid 33116551)
4. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79. (Pubitemid 38249147)
5. Kjeldsen SE, Dahlöf B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy-a Losartan Intervention For Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491-1498.
6. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 1999;41:532-543. (Pubitemid 29130617)
7. Kai H, Kudo H, Takayama N, et al. Large blood pressure variability and hypertensive cardiac remodeling-role of cardiac inflammation. Circ J. 2009;73:2198-2203.
8. Sun M, Dawood F, Wen WH, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221-3228. (Pubitemid 39525069)
9. Kaur K, Sharma AK, Singal PK. Significance of changes in TNF-a and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:H106-H113.
10. Sun M, Chen MY, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 2007;115:1398-1407. (Pubitemid 46648375)
11. Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction-another model of inflammation? Hypertension. 2004;43:739-745. (Pubitemid 38405580)
12. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575. (Pubitemid 46348511)
13. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteina-ses/ tissue inhibitors of metalloproteinases-relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089-2096.
14. Honsho S, Nishikawa S, Amano K, et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ Res. 2009;105:1149-1158.
15. Abbas A, Grant PJ, Kearney MT. Role of IGF-1 in glucose regulation and cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6:1135-1149.
16. McMullen JR. Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease. Clin Exp Pharmacol Physiol. 2008; 35:349-354. (Pubitemid 351257887)
17. Teiger E, Than VD, Richard L, et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 1996;97:2891-2897. (Pubitemid 26197104)
18. Choi YH, Cowan DB, Moran AM, et al. Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J Thorac Cardiovasc Surg. 2009;137:1356-1362.
19. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446: 444-448. (Pubitemid 46474597)
20. Rothermel BA, Hill JA. Autophagy in load-induced heart disease. Circ Res. 2008;103:1363-1369.
21. Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med. 2007;13:619-624. (Pubitemid 46828485)
22. Zhu HX, Tannous P, Johnstone JL, et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest. 2007;117: 1782-1793. (Pubitemid 47036312)
23. Gottlieb RA, Mentzer RM. Autophagy during cardiac stress: joys and frustrations of autophagy. Annu Rev Physiol. 2010;72:45-59.
24. Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol. 2008;44:831-854.
25. Bersell K, Arab S, Haring B, et al. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009;138: 257-270.
26. Boström P, Mann N, Wu J, et al. C/EBPb controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell. 2010;143:1072-1083.
27. Adams TD, Yanowitz FG, Fisher AG, et al. Noninvasive evaluation of exercise training in college-age men. Circulation. 1981;64:958-965. (Pubitemid 11028092)
28. Wu YL, Gu CH, Xu GC, et al. Clinical observation of randomized double-blind and multicenter trial on Qiliqiangxin capsule in the treatment of chronic heart failure. Chin J Difficult Complicated Cases. 2007; 6:55-58.
29. Zhang WD, Chen H, Zhang C, et al. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. Planta Med. 2006;72:4-8. (Pubitemid 43241585)
30. You JS, Huang HF, Chang YL. Panax ginseng reduces adriamycin-induced heart failure in rats. Phytother Res. 2005;19:1018-1024.
31. Ling JH, Wu PB, Cai WY, et al. Therapeutic effect of Qiliqiangxin capsule on the patients with chronic congestive heart failure. Chin J Difficult Complicated Cases. 2008;5:49-55.
32. Xiao H, Song Y, Li Y, et al. Qiliqiangxin regulates the balance between tumor necrosis factor-a and interleukin-10 and improves cardiac function in rats with myocardial infarction. Cell Immunol. 2009;260:51-55.
33. Li JL, Li P, Feng XH, et al. Effects of losartan on pressure overload-induced cardiac gene expression profiling in rats. Clin Exp Pharmacol Physiol. 2003;30:827-832. (Pubitemid 37506147)
34. Zou Y, Akazawa H, Qin YJ, et al. Mechanical stress activates angioten-sin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6:499-506. (Pubitemid 38786592)
35. Li L, Zhou N, Gong H, et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res. 2010;33:1289-1297.
36. Sebastian T, Johnson PF. Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPb. Cell Cycle. 2006;5: 953-957.
37. Li J, Yang P. Inhibition of periostin by Qiliqiangxin to improve ventricular remodeling in heart failure rats. Chin J Lab Diagnos. 2009;13: 170-172.
38. Ryu M, Kim EH, Chun M, et al. Astragali Radix elicits anti-inflammation via activation of MKP-1, concomitant with attenuation of p38 and Erk. J Ethnopharmacol. 2008;115:184-193. (Pubitemid 350266261)
39. Zhao Z, Wang W, Wang F, et al. Effects of astragaloside IV on heart failure in rats. Chin Med. 2009;4:1-6.
40. Zhao P, Su GH, Xiao XY, et al. Chinese medicinal herb Radix Astragali suppresses cardiac contractile dysfunction and inflammation in a rat model of autoimmune myocarditis. Toxicol Lett. 2008;182: 29-35.
41. Zhu WH, Leng XS, Zhu JY. Effect of Shenfu injection on ischemia-reperfusion injury of rat liver graft. Hepatobiliary Pancreat Dis Int. 2006;5:205-209.
42. Lin JS, Chan CY, Yang C, et al. Zhi-Fuzi, a cardiotonic Chinese herb, a new medical treatment choice for portal hypertension? Exp Biol Med (Maywood). 2007;232:557-564. (Pubitemid 46524478)
43. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463-477. (Pubitemid 38456176)
44. Cheng X, Song Y, Liao YH, et al. The effects of traditional drug Qili-qiangxin on inflammatory cytokines expression in rats with acute myo-cardial infarction. Int J Cardiol. 2008;125:S56-S57.
45. Sato H, Watanabe A, Tanaka T, et al. Regulation of the human tumor necrosis factor-alpha promoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and tran-scriptional factors. J Mol Cell Cardiol. 2003;35:1197-1205. (Pubitemid 37163528)